AnHeart and Innovent Releases Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting
HANGZHOU, China, June 06, 2021 (GLOBE NEWSWIRE) — AnHeart Therapeutics Co., Ltd (“AnHeart”), a clinical stage oncology company focused…
